EKF Diagnostics to highlight the product portfolio expansion AACC Clinical Lab Expo -
From the early detection of ketosis in a mutation assay cancer in whole blood
EKF Diagnostics, the International Society of diagnosis, will showcase its expanding product portfolio on its stand subsidiary Stanbio Laboratory # 1933 at the AACC Clinical Lab Expo in Chicago, United States STATES, July 29-31. In addition to demonstrating the success of current products, including ß-HB test Stanbio technology and PointMan ™ technology molecular EKF, new products will be introduced at AACC. These introductions are the result of the recent acquisition of EKF Separation Technology Inc. (STI) and medical DiaSpect.
Clear and specific results ketoacidosis
The Stanbio diagnostic efficacy of beta-hydroxybutyrate enzyme (beta-HB) liquicolor ® test is quickly led his acceptance in hospital laboratories across the United States as the new standard of care in ketosis tests. More than 850 (20%) of US hospitals are now using the test for accurate, specific and quantitative tests of this main ketone produced during ketosis. Therefore, physicians can make more informed clinical decisions is changing how hospitals manage patients with symptoms of ketoacidosis.
The stable reagent liquid liquicolor ß-HB can be used on open channel chemistry analyzers twenty different manufacturers. A point of care option is also available in the form of the STAT-Site ® M ß-HB tape-based testing system.
blood collection Activation for cancer patients monitoring
Since its introduction last year, PointMan ™ DNA enrichment technology now been shown to be sufficiently sensitive to allow the use of a blood sample to assess the mutation status of a cancer patient. Recent studies have shown that the sensitivity of PointMan technology is much larger than the existing PCR technology. PointMan can detect 1 mutant gene in 10,000 copies of normal genes, while competing technologies can detect 1 to 100. This maximizes the use of small samples of biopsy and allows multiplexing mutations in a single test rather than many tests also individual.
New EKF product launches
to be previewed at AACC, the new palm DiaSpect Tm is the fastest system for measuring hemoglobin in the world giving laboratory quality performance to screen for anemia in any environment. Results in 1-2 seconds, this analyzer is CE marked and is currently awaiting approval by the FDA.
The centrifuge new PlasmaPrep ™ will be launched by EKF to AACC. Ideal for use in both the hospital and the laboratory, PlasmaPrep-12 is designed for serum / plasma separation STAT and is perfect for coagulation studies. Enabling the separation of blood fast and easy to use, it is controlled by a microprocessor with four times pre-programmed spin. These include poor plasma mode platelets providing serum or separations plasma in three minutes and fashion plate Platelet Rich Plasma providing a rich plasma in 30 seconds
Julian Baines, CEO of EKF, commented :.
We strengthened product offering and EKF services during the past year thanks to recent acquisitions and product development. This positions EKF to the tip of the provision of hematology tests and point of care also, by Stanbio, as the first reagent suppliers of clinical chemistry. EKF now offers a complete range of products and cost and to participate meaningfully in personalized medicine; an area which is rapidly key within the IVD become industry.
EmoticonEmoticon